Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc Switch in Suppressed HIV-1 Patients (PROTEST)
NCT01378910Phase 4
Key facts
- Status
- Completed
- Start
- Jun 2011
- Primary completion
- Apr 2014
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- maraviroc
- Conditions
- human immunodeficiency virus type 1 infection (HIV-1)
01
Overview
Phase 4, open-label trial of maraviroc in human immunodeficiency virus type 1 infection (HIV-1). Primary endpoint: Percentage of patients with viral load under 50 copies/mL at 48 weeks. Started Jun 2011; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
HIV-1 infected adults on stable ART for 6 months with viral load < 50 copies/mL and R5 tropism (proviral DNA) needing a switch due to toxicity.
04
Endpoints
Primary
Percentage of patients with viral load under 50 copies/mL
Secondary
Percentage of patients without confirmed virological failure
Beyond the preview
Go deeper on NCT01378910.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01378910.